Egbert Miranda, MD
Endocrinology, Diabetes & Metabolism · Corpus Christi, TXNPI 1093785230
Payments from drug & device makers
Across 125 payments — averaging $24.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$472
- Lilly USA, LLC$362
- Mannkind Corporation$336
- Abbott$315
- Amgen$253
- Novo Nordisk$197
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,96297%
- Education$191%
- Gifts$592%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 12 | $472 |
| Lilly USA, LLC | 15 | $362 |
| Mannkind Corporation | 12 | $336 |
| Abbott | 17 | $315 |
| Amgen | 11 | $253 |
| Novo Nordisk | 12 | $197 |
| Recordati_rare_diseases_inc. | 3 | $192 |
| AstraZeneca | 2 | $129 |
| Insulet Corporation | 6 | $121 |
| Sanofi-aventis U.S. LLC | 5 | $110 |
| Novartis | 3 | $71 |
| Merck | 4 | $57 |
| Tandem Diabetes Care, Inc. | 3 | $48 |
| Sequel Med Tech, LLC | 2 | $43 |
| EUSA Pharma (US) LLC | 1 | $41 |
| Cequr Corporation | 2 | $39 |
| Boehringer Ingelheim | 2 | $34 |
| Ascendis Pharma Endocrinology Inc | 1 | $30 |
| Radius Health, Inc. | 2 | $29 |
| Medtronic | 1 | $28 |
| Sandoz | 1 | $25 |
| Corcept Therapeutics | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Dexcom, Inc. | 1 | $15 |
| Optos, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| GRT US Holding, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,055 in reported general payments places this provider in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 313 | $267,146 |
| OzempicSemaglutide | 223 | $264,579 |
| MounjaroTirzepatide | 89 | $121,820 |
| TrulicityDulaglutide | 47 | $64,110 |
| Tresiba Flextouch U-100Insulin Degludec | 128 | $63,449 |
| Lyumjev Kwikpen U-100Insulin Lispro-Aabc | 101 | $57,857 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $37,569 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 52 | $31,028 |
| FarxigaDapagliflozin Propanediol | 18 | $19,652 |
| Bydureon BciseExenatide Microspheres | 12 | $19,190 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $18,922 |
| Humalog Kwikpen U-100Insulin Lispro | 76 | $17,137 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $16,883 |
| KerendiaFinerenone | 19 | $16,819 |
| Novolog FlexpenInsulin Aspart | 84 | $13,396 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $34 | $267,146313 claims |
| Novo NordiskOzempic | $197 | $264,579223 claims |
| Lilly USA, LLCMounjaro, Trulicity | $362 | $185,930136 claims |
| AstraZenecaFarxiga | $129 | $19,65218 claims |
| BayerKerendia | $472 | $16,81919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Corpus Christi
- Osvaldo BruscoCorpus Christi$2.2M
- Brandi AddisonCorpus Christi$652K
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.